Atrium Therapeutics, Inc. (RNA)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price

$8.33

Day

-9.65%

Market cap

$142.49M

Close 2026-09-23.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

• Sessa Capital IM, L.P. — $20.18M
• SUSQUEHANNA INTERNATIONAL GROUP, LLP — $11.31M
• VANGUARD CAPITAL MANAGEMENT LLC — $9.83M
• CRCM LP — $8.63M
• CRCM LP — $8.63M
• CRCM LP — $7.84M
• BlackRock, Inc. — $7.8M
• TIG Advisors, LLC — $7.55M

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

• Hughes Steven George (Chief Medical Officer) sold 2,017 shares at $72.45 on 2026-01-21
• Hughes Steven George (Chief Medical Officer) sold 2,878 shares at $72.45 on 2026-01-21
• Boyce Sarah (President and CEO) sold 6,394 shares at $72.45 on 2026-01-21
• Boyce Sarah (President and CEO) sold 7,993 shares at $72.45 on 2026-01-21
• Flanagan W. Michael (Chief Scientific Officer) sold 2,558 shares at $72.45 on 2026-01-21
• Flanagan W. Michael (Chief Scientific Officer) sold 3,976 shares at $72.45 on 2026-01-21

Recent filings

• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• 4 — 2026-09-22
• SCHEDULE 13G — 2026-08-14
• SCHEDULE 13G/A — 2026-08-14